Pfizer bought Global Blood Therapeutics Global Blood Therapeutics from 10/5/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Pfizer completed its acquisition of Global Blood Therapeutics for $5.4, or $68.5 per share.

Global Blood Therapeutics

Review

Source:

{source} pictogram

investors.pfizer.com

Vladimir Petenev

News editor

Write your comment first

News feed

Acron reports for 2023 under RAS

3/29/24 AKRN

TGC-14 reported for 2023 by IFRS

3/29/24 TGKN

Levenguc reported for 2023 by RAS

3/29/24 LVHK

NLMK reported for 2023 by RAS

3/29/24 NLMK

NPO Nauka reported for 2023 by RAS

3/29/24 NAUK

SFI reported for 2023 according by RAS

3/29/24 SFIN

Severstal increased productivity of mill 2000 at CherMK

3/29/24 CHMF

Lukoil expects to restore the Nizhny Novgorod refinery in 1-2 months

3/29/24 LKOH

Svetofor reported for 2023 by RAS

3/29/24 SVET

Korshunovsky GOK reported for 2023 by RAS

3/29/24 KOGK